Amphastar Pharmaceuticals, Inc. (29A.F)

38,74 -0,01 (-0,03%) Ab 08:12AM CEST. Markt geöffnet.

Amphastar Pharmaceuticals, Inc.

11570 6th Street
Rancho Cucamonga, CA 91730
United States
909 980 9484
https://www.amphastar.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 1.761

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Ziping Luo Ph.D.	Chairman of the Board, Chief Scientist & COO	1,28M	N/A	1950
Dr. Yongfeng Zhang Ph.D.	Co-Founder, President, CEO, Chief Scientific Officer & Director	1,88M	N/A	1947
Mr. William J. Peters M.B.A.	CFO, Executive VP of Finance, Treasurer & Director	1,14M	6,72M	1968
Mr. Jacob Liawatidewi M.B.A.	Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director	825,13k	1,36M	1974
Mr. Rong Zhou M.S.	Senior Executive Vice President of Production	902,19k	935,06k	1959
Dan Dischner M.B.A.	Vice President of Human Resources & Corporate Communication	N/A	N/A	N/A
Tony Marrs M.B.A., M.P.H.	Senior VP of Regulatory Affairs & Clinical Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Corporate Governance

Amphastar Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 29. April 2024, lautet 6. Die grundlegenden Scores sind Audit: 4, Vorstand: 9, Shareholderrechte: 5, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.